[1]
|
Simsek, M., Tekin, S.B. and Bilici, M.J. (2018) Immunological Agents Used In Cancer Treatment. The Eurasian Journal of Medicine, 51, 90-94. https://doi.org/10.5152/eurasianjmed.2018.18194
|
[2]
|
Thompson, J.A., Schneider, B.J., Brahmer, J., Andrews, S. and Engh, A.J. (2020) NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. Journal of the National Comprehensive Cancer Network, 18, 230-241. https://doi.org/10.6004/jnccn.2020.0012
|
[3]
|
Tajiri, K. and Ieda, M. (2019) Cardiac Complications in Immune Checkpoint Inhibition Therapy. Frontiers in Cardiovascular Medicine, 6, Article No. 3. https://doi.org/10.3389/fcvm.2019.00003
|
[4]
|
皋文君, 刘砚燕, 袁长蓉. 国际肿瘤化疗药物不良反应评价系统——通用不良反应术语标准4.0版[J]. 肿瘤, 2012, 32(2): 142-144.
|
[5]
|
中国抗癌协会整合肿瘤心脏病学分会, 中华医学会心血管病学分会肿瘤心脏病学学组, 中国医师协会心血管内科医师分会肿瘤心脏病学专业委员会, 中国临床肿瘤学会肿瘤心脏病学专家委员会. 免疫检查点抑制剂相关心肌炎监测与管理中国专家共识(2020版) [J]. 中国肿瘤临床, 2020, 47(20): 1027-1038.
http://doi.org/10.3969/j.issn.1000-8179.2020.20.148
|
[6]
|
Moslehi, J.J., Salem, J.E., Sosman, J.A., Lebrun-Vignes, B. and Johnson, D. (2018) Increased Reporting of Fatal Immune Checkpoint Inhibitor-Associated Myocarditis. The Lancet, 391, 933.
https://doi.org/10.1016/S0140-6736(18)30533-6
|
[7]
|
Wang, F., Sun, X., Qin, S., Hua, H. and Yang, M. (2020) A Retrospective Study of Immune Checkpoint Inhibitor-Associated Myocarditis in a Single Center in China. Chinese Clinical Oncology, 9, Article No. 16.
https://doi.org/10.21037/cco.2020.03.08
|
[8]
|
Wang, F., Qin, S.K., Lou, F., Chen, F.X., Shi, M.Q., Liang, X.H., Jiang, H., Jiang, Y., Chen, Y., Du, Y.Y., Xue, J., Zhu, H. and Ren, W. (2020) Retrospective Analysis of Immune Checkpoint Inhibitor-Associated Myocarditis from 12 Cancer Centers in China. Journal of Clinical Oncology, 3, e15130.
https://doi.org/10.1200/JCO.2020.38.15_suppl.e15130
|
[9]
|
Advani, P.P., Ballman, K.V., Dockter, T.J., Colon-Otero, G. and Perez, E.A. (2016) Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial. Journal of Clinical Oncology, 34, 581-587.
https://doi.org/10.1200/JCO.2015.61.8413
|
[10]
|
黄光明, 贺盛发, 黄振光, 张宏亮. 15例帕博利珠单抗致免疫相关性心肌炎的病例分析[J]. 中国药房, 2021, 32(6): 729-735.
|
[11]
|
崔亚萌, 齐新, 魏丽萍, 刘玥. 顺铂心脏毒性的研究进展[J]. 现代药物与临床, 2017, 32(2): 351-355.
|
[12]
|
董爽, 胡胜, 欧武陵, 蔡茜. 免疫检查点抑制剂的心脏毒性及其机制[J]. 肿瘤防治研究, 2018, 45(11): 858-863.
|
[13]
|
吴军. 抗肿瘤血管生成药物不良反应的发生机制及处理[J]. 医学综述, 2016, 22(16): 3154-3157.
|
[14]
|
Lyon, A.R., Yousaf, N., Battisti, N.M.L., Moslehi, J. and Larkin, J. (2018) Immune Checkpoint Inhibitors and Cardiovascular Toxicity. The Lancet Oncology, 19, e447-e458. https://doi.org/10.1016/S1470-2045(18)30457-1
|
[15]
|
Jain, V., Bahia, J., Mohebtash, M. and Barac, A. (2017) Cardiovascular Complications Associated With Novel Cancer Immunotherapies. Current Treatment Options in Cardiovascular Medicine, 19, Article No. 36.
https://doi.org/10.1007/s11936-017-0532-8
|
[16]
|
Bonaca, M.P., Olenchock, B.A., Salem, J.E., Wiviott, S.D., Ederhy, S., Cohen, A., Stewart, G.C., Choueiri, T.K., Di Carli, M., Allenbach, Y., Kumbhani, D.J., Heinzerling, L., Amiri-Kordestani, L., Lyon, A.R., Thavendiranathan, P., Padera, R., Lichtman, A., Liu, P.P., Johnson, D.B. and Moslehi, J. (2019) Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology. Circulation, 140, 80-91.
https://doi.org/10.1161/CIRCULATIONAHA.118.034497
|
[17]
|
Mahmood, S.S., Fradley, M.G., Cohen, J.V., Nohria, A., Reynolds, K.L., Heinzerling, L.M., Sullivan, R.J., Damrongwatanasuk, R., Chen, C.L., Gupta, D., Kirchberger, M.C., Awadalla, M., Hassan, M.Z.O., Moslehi, J.J., Shah, S.P., Ganatra, S., Thavendiranathan, P., Lawrence, D.P., Groarke, J.D. and Neilan, T.G. (2018) Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. Journal of the American College of Cardiology, 71, 1755-1764.
https://doi.org/10.1016/j.cjca.2018.03.012
|
[18]
|
Mir, H., Alhussein, M., Alrashidi, S., Alzayer, H., Alshatti, A., Valettas, N., Mukherjee, S.D., Nair, V. and Leong, D.P. (2018) Cardiac Complications Associated With Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area. The Canadian Journal of Cardiology, 34, 1059-1068.
https://doi.org/10.1016/j.cjca.2018.03.012
|
[19]
|
Nieminen, M.S., Heikkilä, J. and Karjalainen, J. (1984) Echocardiography in Acute Infectious Myocarditis: Relation to Clinical and Electrocardiographic Findings. The American Journal of Cardiology, 53, 1331-1337.
https://doi.org/10.1016/0002-9149(84)90089-4
|
[20]
|
Palaskas, N., Lopez-Mattei, J., Durand, J.B., Iliescu, C. and Deswal, A. (2020) Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. Journal of the American Heart Association, 9, e013757. https://doi.org/10.1161/JAHA.119.013757
|
[21]
|
Atallah-Yunes, S.A., Kadado, A.J., Kaufman, G.P. and Hernandez-Montfort, J. (2019) Immune Checkpoint Inhibitor Therapy and Myocarditis: A Systematic Review of Reported Cases. Journal of Cancer Research and Clinical Oncology, 145, 1527-1557. https://doi.org/10.1007/s00432-019-02927-x
|
[22]
|
Brahmer, J.R., Lacchetti, C., Schneider, B.J., Atkins, M.B., Brassil, K.J., Caterino, J.M., Chau, I., Ernstoff, M.S., Gardner, J.M., Ginex, P., Hallmeyer, S., Holter Chakrabarty, J., Leighl, N.B., Mammen, J.S., McDermott, D.F., Naing, A., Nastoupil, L.J., Phillips, T., Porter, L.D., Puzanov, I., Reichner, C.A., Santomasso, B.D., Seigel, C., Spira, A., Suarez-Almazor, M.E., Wang, Y., Weber, J.S., Wolchok, J.D. and Thompson, J.A. (2018) Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 36, 1714-1768.
https://doi.org/10.1200/JCO.2017.77.6385
|
[23]
|
Norwood, T.G., Westbrook, B.C., Johnson, D.B., Litovsky, S.H., Terry, N.L., McKee, S.B., Gertler, A.S., Moslehi, J.J. and Conry, R.M. (2017) Smoldering Myocarditis Following Immune Checkpoint Blockade. Journal for Immunotherapy of Cancer, 5, 91. https://doi.org/10.1186/s40425-017-0296-4
|
[24]
|
Arangalage, D., Delyon, J., Lermuzeaux, M., Ekpe, K., Ederhy, S., Pages, C. and Lebbé, C. (2017) Survival after Fulminant Myocarditis Induced by Immune-Checkpoint Inhibitors. Annals of Internal Medicine, 167, 683-684.
https://doi.org/10.7326/L17-0396
|
[25]
|
Frigeri, M., Meyer, P., Banfi, C., Giraud, R., Hachulla, A.L., Spoerl, D., Friedlaender, A., Pugliesi-Rinaldi, A. and Dietrich, P.Y. (2018) Immune Checkpoint Inhibitor-Associated Myocarditis: A New Challenge for Cardiologists. The Canadian Journal of Cardiology, 34, 92.e1-92.e3. https://doi.org/10.1016/j.cjca.2017.09.025
|
[26]
|
Tay, R.Y., Blackley, E., McLean, C., Moore, M., Bergin, P., Gill, S. and Haydon, A. (2017) Successful Use of Equine Anti-Thymocyte Globulin (ATGAM) for Fulminant Myocarditis Secondary to Nivolumab Therapy. British Journal of Cancer, 117, 921-924. https://doi.org/10.1038/bjc.2017.253
|